• Hyperphosphatemia

Renvela Generic Name & Formulations

General Description

Sevelamer carbonate 800mg; tabs.

Pharmacological Class

Phosphate binder.

How Supplied

Tabs—30, 270; Packets—90


Renvela Indications


Control of serum phosphorus in patients ≥6yrs with chronic kidney disease on dialysis.

Renvela Dosage and Administration


Take with meals. Patients not taking a phosphate binder: serum phosphorus >5.5 and <7.5mg/dL: 800mg 3 times daily; ≥7.5mg/dL: 1.6g 3 times daily. Titrate by 800mg/meal at 2-week intervals to serum phosphorus target range; average max 7.2g/day. Switching from sevelamer HCl or switching between sevelamer carbonate tabs and pwd: use same dose in grams. Switching from calcium acetate: sevelamer carbonate 800mg approximates calcium acetate 667mg (see full labeling).


<6yrs: not established. ≥6yrs: Take with meals. Patients not taking a phosphate binder: BSA: ≥0.75–<1.2m2: 800mg 3 times daily; titrate by 400mg/dose at 2-week intervals to achieve target levels; ≥1.2m2: 1.6g 3 times daily; titrate by 800mg/dose at 2-week intervals to achieve target levels.

Renvela Contraindications


Bowel obstruction.

Renvela Boxed Warnings

Not Applicable

Renvela Warnings/Precautions


Dysphagia. Swallowing disorders (use susp. form). Severe GI motility disorders. Major GI tract surgery. Pregnancy.

Renvela Pharmacokinetics

See Literature

Renvela Interactions


Concomitant with drugs that have a narrow therapeutic index; monitor. Consider separation of administration with cyclosporine, tacrolimus, or levothyroxine. Separate dosing of ciprofloxacin by ≥2hrs before or 6hrs after sevelamer; mycophenolate mofetil by ≥2hrs before sevelamer.

Renvela Adverse Reactions

Adverse Reactions

Nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, constipation; rare: bowel obstruction, perforation.

Renvela Clinical Trials

See Literature

Renvela Note

Not Applicable

Renvela Patient Counseling

See Literature